4507:TYO
Shionogi & Co Ltd
¥3,172.00
arrow_upward
+1.08%(+34.00) 1D
Nov 13, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4507...
Open
¥3,117
High
¥3,188
Low
¥3,101
Mkt. cap
2.82T
Avg. vol.
3.32M
Volume
2.83M
Dividend
2.46%
Quarterly dividend
¥19
Ex-dividend date
Mar 30, 2027
P/E ratio
11.19
52-wk high
¥3,758
52-wk low
¥2,584
EPS
¥283
Shares outstanding
314.50M
No. of employees
6K
Open
¥3,117
High
¥3,188
Low
¥3,101
Mkt. cap
2.82T
Avg. vol.
3.32M
Volume
2.83M
Dividend
2.46%
Quarterly dividend
¥19
Ex-dividend date
Mar 30, 2027
P/E ratio
11.19
52-wk high
¥3,758
52-wk low
¥2,584
EPS
¥283
Shares outstanding
314.50M
No. of employees
6K
News stories
From web sources and news partners
Reuters
·
11 minutes ago
Goldman Sachs sees S&P 500 rising to 8,700 next year despite slower earnings growth
ChartMill
·
1 hour ago
S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall
Yahoo Finance
·
1 hour ago
The S&P 500 Recently Experienced Its Worst Day Since 2025. Here's Why Investors Shouldn't Worry.
FOREX.com
·
2 hours ago
S&P 500 forecast: SPX struggles for direction ahead of PPI data
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees6.22K
FoundedJun 5, 1919
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteshionogi.com